Alicaforsen: ISIS began a European Phase III trial of alicaforsen (ISIS 2302) in up to 150 patients with active Crohn's disease. The primary endpoint of the dou

Isis Pharmaceuticals Inc. (ISIS), Carlsbad, Calif.
Product: Alicaforsen ( ISIS 2302)

Read the full 121 word article

How to gain access

Continue reading with a
two-week free trial.